What chance do you think this gives for one or more near term analyst upgrades?
Not to mention potential near term analyst upgrades, likely positive CHMP opinion on Mabthera SC in 3 weeks, and interesting revenue numbers (including $10 million Herceptin payment by Roche) for Q3 in Nov., Pfizer deal updates, etc.
You mean of course the actual price values of 10.4K shares at $11.31 and close at $11.13 - yes a good sign
...on their web site under the investor relations tab
Herceptin and Mabthera sales both up 6% this quarter. Bodes well for commissions for HALO partnerships.
Analyst just asked for more info about filing. Baxter added that FDA has asked no additional questions and that assuming approval, HyQvia launch will be in H2 2014. They later added that they continue reimbursement in one European country for HyQvia, and will also continue to "nail down reimbursement" in several other European countries this year.
Sentiment: Strong Buy
Someone collected shares above $12 in post-market yesterday and pre-market today, plus more in high $11's so this may well be bottom and last time ever at $11.50-$11.60
And...you haven't mentioned HTI-501 much or lately, which had positive-looking early results shared on June 29th for their current phase 1/2 cellulite study. I think it is wholly owned by halo and if I remember correctly from some article, the estimated market for cellulite alone dwarfs most or all of the other drugs halo is partnered with. That is not to even mention how HTI-501 could also help with other conditions such as aesthetic and connective tissue disorders like keloid and hypertrophic scarring, localized scleroderma, frozen shoulder syndrome and Dupuytren's contracture.
I bring this up since it seems to me HTI-501 is the often overlooked giant in terms of potential future revenues.
Halo's partnership with Roche's on Actemra SC isn't mentioned much since it is a ways out, having only completed phase I at this point.
Nonetheless, I know how Fezz likes to keep up on such things, so just to note that it seems positive for the partnership regarding future FDA approvals that Roche was yesterday granted their sixth FDA approval for ACTEMRA in four years for use in adult patients living with moderately to severely active rheumatoid arthritis.
The one that received approval was not, but check on Halozyme's site in their pipeline and you will see there that some form of Actemra SC is partnered with Roche.
Quite likely. Not that it matters really, since this company has tremendous value and growing, but Herceptin SC CHMP announcement was around 11:40am EST, a bit after the London stock exchange closes, so likely the same will happen again.
Baxter said in their cc they will refile with FDA for HyQ. Can he estimate a date when this will happen with press release?
Thanks for offering to ask our questions.
250M into 4.5B is 5.5% (not 10%), even if extra allowance used, dilution is under 6.5%.
At today's close of just under $69/shr, that means about 4 million shares, which at today's volume would trade under one day.
Dilution will be based on $250M into company market cap, not share price sold to brokerages. Given that share price hit $74 last week and Yelp beat on revenues both this quarter and also raised revenue guidance for the year, dilution could be somewhat less than you say. Look at history for INSM (few months ago), Pandora, and various others, and you will see that public share price (hence market cap) rose with a new offering (hence dilution dropped), which is to say that company value increased when the company is in a strong position like Yelp is.
0 out of 23 analysts (=none) say sell or strong sell, every one says hold, buy, or strong buy, as does Cramer who suggested only few days ago that it would be smart for Yelp to raise money and also rated it a buy going into earnings knowing how that would help its growth, so perhaps wise to assume 24 experts are not wrong, even if there is a dip short term.